Abstract: Prostate cancer particularly hormone-unresponsive metastatic prostate cancer, is treated by cyclophosphamide or other normally substantially inactive agent. Potentiation of the anti-cancer activity and amelioration of cyclophosphamide-associated toxicity is achieved by an initial intravenous infusion of DPPE over an approximately one hour period prior to cyclophosphamide treatment.

Abstract: The invention relates to a pharmaceutical agent which is suitable for subcutaneous injection of protein C, wherein it comprises protein C and a pharmaceutically acceptable carrier.

Abstract: Topical ophthalmic compositions for treatment of the eye are provided which comprise aqueous mixtures of a non-steroidal agent having a pKa, a pH, and a concentration of agent chosen so as to maintain at least a therapeutic amount of the agent in suspension and a therapeutic amount of the agent in solution. A method for treating diseases of the eye, including inflammation, is also provided by topically applying such aqueous mixtures to eyes in need of treatment, whereby the therapeutic amount of the drug in solution has an immediate therapeutic effect at full concentration, and the therapeutic amount of drug in suspension has a delayed therapeutic effect by release from the suspension over a period of time by reason of dissolution kinetics.

Abstract: The present invention provides a novel use of a compound of formula I ##STR1## or a pharmaceutically and/or physiologically acceptable salt or solvate thereof for the manufacture of a pharmaceutical composition useful for lowering intraocular pressure.